NCIt definition : A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine
protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib
binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation
of AKT substrates that mediate cellular processes, such as cell division, apoptosis,
and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies
show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components.
By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be
used as monotherapy or combination therapy for a variety of human cancers.;
https://www.has-sante.fr/jcms/p_3521945/fr/truqap-capivasertib-cancer-du-sein 2024 false false false France evaluation of the transparency committee Capivasertib capivasertib capivasertib